Triac Trial II in MCT8 Deficiency Patients

计划入组 22 人 · 首次发布于 2015 年 3 月 24 日

Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients

计划入组 46 人 · 首次发布于 2014 年 2 月 12 日

Study With a Topical Gel Containing TRIAC and DHEA in Subjects With Skin Atrophy Due to Glucocorticoids

计划入组 10 人 · 首次发布于 2018 年 12 月 21 日

Triacetin

C₉H₁₄O₆

Troleandomycin

C₄₁H₆₇NO₁₅

Triacetylchitotriose

C₂₄H₄₁N₃O₁₆

Triax Pharmaceuticals, Llc.

United States

Swiss GO Trial Group

Switzerland

Trial Management Group Inc.

Canada

European Commission Approves Emcitate (Tiratricol) as First Treatment for MCT8 Deficiency

Egetis' Emcitate NDA for MCT8 Deficiency Advances Toward September 28, 2026 FDA Decision

New International Guideline Published for Diagnosing and Treating Allan-Herndon-Dudley Syndrome